东南亚市场再下一城：上海医药附属公司利伐沙班片在泰国获批上市

财中社05-07

　　5月7日，上海医药（601607/02607）发布公告，公司下属常州制药厂有限公司生产的利伐沙班片收到泰国食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。

　　利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险、治疗和预防深静脉血栓形成、用于治疗肺栓塞及预防急性病患者静脉血栓栓塞等。

　　截至本公告日，公司针对该药品在东南亚市场上市另投入的研发费用约324.82万元。

　　2026年一季度，上海医药实现收入752.62亿元，归母净利润14.18亿元。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2633116429?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-07 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633116429","market":"hk","top_or_hot":-1,"title":"东南亚市场再下一城：上海医药附属公司利伐沙班片在泰国获批上市","media":"财中社","content":"<html><body><div>\n<p>　　5月7日，<span><a href=\"https://laohu8.com/S/601607\">上海医药</a></span>（601607/02607）发布公告，公司下属常州制药厂有限公司生产的利伐沙班片收到泰国食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。</p><p>　　利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险、治疗和预防深静脉血栓形成、用于治疗肺栓塞及预防急性病患者静脉血栓栓塞等。</p><p>　　截至本公告日，公司针对该药品在东南亚市场上市另投入的研发费用约324.82万元。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.02607\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/02607\">上海医药</a></span>实现收入752.62亿元，归母净利润14.18亿元。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东南亚市场再下一城：上海医药附属公司利伐沙班片在泰国获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东南亚市场再下一城：上海医药附属公司利伐沙班片在泰国获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　5月7日，<span><a href=\"https://laohu8.com/S/601607\">上海医药</a></span>（601607/02607）发布公告，公司下属常州制药厂有限公司生产的利伐沙班片收到泰国食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。</p><p>　　利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险、治疗和预防深静脉血栓形成、用于治疗肺栓塞及预防急性病患者静脉血栓栓塞等。</p><p>　　截至本公告日，公司针对该药品在东南亚市场上市另投入的研发费用约324.82万元。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.02607\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/02607\">上海医药</a></span>实现收入752.62亿元，归母净利润14.18亿元。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202605073730110589.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0020","symbol_name":"浦东新区","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605073730110589.html","article_id":"2633116429","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633116429","pubTimestamp":1778142960,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"5月7日，上海医药（601607/02607）发布公告，公司下属常州制药厂有限公司生产的利伐沙班片收到泰国食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险、治疗和预防深静脉血栓形成、用于治疗肺栓塞及预防急性病患者静脉血栓栓塞等。截至本公告日，公司针对该药品在东南亚市场上市另投入的研发费用约324.82万元。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0099":"上海本地重组","BK0209":"零售","BK0183":"MSCI概念","BK0028":"国家队","BK0188":"融资融券","IPOS":"Renaissance International IPO ETF","BK0012":"证金概念","BK0175":"白马股","BK0184":"上海国资改革","BK0196":"行业龙头","BK0187":"一线龙头","02607":"上海医药","BK0097":"医药电商"},"translate_title":"Another city in Southeast Asia: Rivaroxaban tablets, a subsidiary of Shanghai Pharmaceuticals, were approved for marketing in Thailand","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1.5,"02607":1.5,"IPOS":1.5},"content_text":"5月7日，上海医药（601607/02607）发布公告，公司下属常州制药厂有限公司生产的利伐沙班片收到泰国食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。　　利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险、治疗和预防深静脉血栓形成、用于治疗肺栓塞及预防急性病患者静脉血栓栓塞等。　　截至本公告日，公司针对该药品在东南亚市场上市另投入的研发费用约324.82万元。　　2026年一季度，上海医药实现收入752.62亿元，归母净利润14.18亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633116429","isCrawlerRequest":true}